AFP and hepatocellular carcinoma: Moreover, another study in 2020 showed the superiority of AFP, along with ALT, AST, and NLR, as a combined biomarker system for HBV-HCC diagnosis relative to the use of each single biomarker or any other combinations in patients [37].